Log In
Print
BCIQ
Print
Print this Print this
 

Bydureon (Exenatide once weekly)

Also known as: Byetta LAR, exenatide LAR (AC2993 LAR)

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionLong-acting release (LAR) formulation of synthetic exendin-4
Molecular Target Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R)
Mechanism of ActionGlucagon-like peptide-1 (GLP-1) receptor agonist
Latest Stage of DevelopmentMarketed
IndicationDiabetes
Partner

Alkermes plc
 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today